Semaglutide's Expanding Reach: From Waistlines to Kidneys, Liver, and Brain

Clinicians have suspected for years that semaglutide does more for people without diabetes than those with it. A systematic review and meta-analysis published in Pharmaceuticals in 2025 puts a number on the gap. Across nine randomized controlled trials of once-weekly subcutaneous semaglutide 2.4 mg, adults with type 2 diabetes lost a weighted mean of 6.34% of body weight, while adults without diabetes lost 11.57% — nearly double the effect, with negligible between-study heterogeneity in the diabetic arm.

Why the split? The authors point toward differences in baseline insulin resistance, counter-regulatory hormones, and possibly the metabolic ceiling imposed by diabetes itself. For the quantified-self reader, the practical implication is narrower than it sounds: trial-grade weight loss numbers cited in marketing materials almost always come from non-diabetic cohorts, and a patient with T2D budgeting against those figures is likely to be disappointed.

The renal story has been building since the FLOW trial, but real-world cohorts matter because they include the patients trial protocols often exclude. A multicenter retrospective study of 156 patients with type 2 diabetes and chronic kidney disease, followed for at least two years, reported that the median eGFR slope improved from -3.29 to -0.79 mL/min/1.73 m²/year after semaglutide initiation (p < 0.001). The effect held in the subgroup with baseline eGFR under 60, and in patients on concurrent SGLT2 inhibitors — a combination increasingly treated as standard of care in advanced diabetic kidney disease.

One important boundary: patients with very heavy albuminuria — over 1000 mg/g — did not show a statistically significant slope change. The benefit, in other words, appears most reliably in patients whose kidneys are declining but not yet collapsing. Semaglutide also nudged BMI, HbA1c, triglycerides, and CRP downward, which makes mechanistic attribution messy: is the kidney protection direct, or a downstream consequence of better metabolic control? The honest answer is that this dataset cannot separate them.

Multiple system atrophy is the kind of disease that humbles drug developers. It is rare, fast-moving, and uniformly fatal. So a randomized open-label trial of weekly exenatide 2 mg in 50 MSA patients, published in Annals of Neurology, is a genuinely notable data point. After 48 weeks, the UMSARS parts I+II combined score worsened by 6.1 points in the exenatide arm versus 13.3 in controls — an adjusted mean difference of -7.4 points (p = 0.0003).

The caveats are loud. The trial was single-center and open-label, so expectancy effects in a subjective rating scale cannot be ruled out. Secondary outcomes — falls, speech, swallowing, timed walking, quality of life, cognition — did not reach statistical significance at 48 or 96 weeks. Neurofilament light chain, CSF alpha-synuclein oligomers, and imaging biomarkers were similarly quiet. A proof-of-concept signal in a small open-label cohort is exactly that: a reason to run the next, bigger, blinded trial. It is not yet a reason for anyone with MSA to seek exenatide off-label.

For metabolic dysfunction-associated steatotic liver disease — the condition formerly known as NAFLD — a 2025 plain-language summary in Postgraduate Medicine walks patients through where GLP-1 receptor agonists currently sit in the emerging MASLD treatment landscape. The framing is patient-facing rather than mechanistic, which is its own signal: regulators and societies are now comfortable enough with the indication-adjacent evidence to communicate it to non-specialists. Resmetirom remains the only FDA-approved MASH-specific agent, but GLP-1s — and the dual and triple agonists behind them — are increasingly part of the conversation.

A 2025 review in Panminerva Medica surveys what comes next. The headline molecule is retatrutide — a triple GLP-1, GIP, and glucagon receptor agonist whose phase II weight-loss data are approaching the 20–30% range historically reserved for bariatric surgery. Amylin co-agonists, GIP antagonists paired with GLP-1, and non-entero-pancreatic mechanisms are all in development. For a field that spent a decade asking whether any drug could match the metabolic effects of a Roux-en-Y gastric bypass, this is a meaningful inflection.

The 2025 cycle does not deliver a unified theory of GLP-1 biology, but it does sharpen the map. The weight-loss effect is real and roughly twice as large in people without diabetes. The kidney effect is plausibly real in the moderate-risk diabetic CKD population, less clear in the heaviest proteinuric patients. The neuroprotection signal in MSA is a proof-of-concept, not a verdict. The MASLD chapter is being written in real time. And the pipeline behind semaglutide is preparing to push the ceiling higher.

For an audience that loves a clean protocol, the unsatisfying truth is that GLP-1 medicine is still in its enumeration phase — counting up the organs that respond, before anyone can tell you exactly why. The most rigorous posture, for now, is curious skepticism: take the strong signals seriously, hold the weak ones lightly, and let the next round of trials do the sorting.